The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Open accessAbstract
BACKGROUND: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata. METHODS: We conducted two randomized, placebo-controlled, phase 3 trials (BRAVE-AA1 and BRAVE-AA2) involving adults with severe alopecia areata with a Severity of Alopecia Tool (SALT) score of 50 or higher (range, 0 [no scalp hair loss] to 100 [complete scalp hair loss]). Patients were randomly assigned in a 3:2:2 ratio to receive once-daily baricitinib at a dose of 4 mg, baricitinib at a dose of 2 mg, or placebo. The primary outcome was a SALT score of 20 or less at week 36. RESULTS: We enrolled 654 patients in the BRAVE-AA1 trial and 546 in the BRAVE-AA2 trial. The estimated percentage of patients with a SALT score of 20 or less at week 36 was 38.8% with 4-mg baricitinib, 22.8% with 2-mg baricitinib, and 6.2% with placebo in BRAVE-AA1 and 35.9%, 19.4%, and 3.3%, respectively, in BRAVE-AA2. In BRAVE-AA1, the difference between 4-mg baricitinib and placebo was 32.6 percentage points (95% confidence interval [CI], 25.6 to 39.5), and the difference between 2-mg baricitinib and placebo was 16.6 percentage points (95% CI, 9.5 to 23.8) (P<0.001 for each dose vs. placebo). In BRAVE-AA2, the corresponding values were 32.6 percentage points (95% CI, 25.6 to 39.6) and 16.1 percentage points (95% CI, 9.1 to 23.2) (P<0.001 for each dose vs. placebo). Secondary outcomes for baricitinib at a dose of 4 mg but not at a dose of 2 mg generally favored baricitinib over placebo. Acne, elevated levels of creatine kinase, and increased levels of low- and high-density lipoprotein cholesterol were more common with baricitinib than with placebo. CONCLUSIONS: In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. Longer trials are required to assess the efficacy and safety of baricitinib for alopecia areata. (Funded by Eli Lilly under license from Incyte; BRAVE-AA1 and BRAVE-AA2 ClinicalTrials.gov numbers, NCT03570749 and NCT03899259.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W. V., et al. (2010) · Nature · doi:10.1038/nature09114 · Cited by 830
Self-citationAlopecia areata investigational assessment guidelines–Part II
Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., McMichael, A. J., Randall, V. A., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.032 · Cited by 798
Self-citationPratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.11 · Cited by 787
JAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Self-citationSafety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Self-citationLymphocytes, neuropeptides, and genes involved in alopecia areata
Gilhar, A., Paus, R., & Kalish, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31942 · Cited by 306
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016) · JCI Insight · doi:10.1172/jci.insight.89790 · Cited by 297
Strazzulla, L. C., Wang, E. H. C., Avila, L., Lo Sicco, K., Brinster, N., Christiano, A. M., & Shapiro, J. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.04.1142 · Cited by 263
Blume-Peytavi, U., Blumeyer, A., Tosti, A., Finner, A., Marmol, V., Trakatelli, M., Reygagne, P., Messenger, A., & the European Consensus Group (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10011.x · Cited by 234
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.015 · Cited by 233
Self-citationJAK inhibitors for alopecia areata: a systematic review and meta‐analysis
Phan, K., & Sebaratnam, D. F. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15489 · Cited by 213
Meah, N., Wall, D., York, K., Bhoyrul, B., Bokhari, L., Sigall, D. A., Bergfeld, W. F., Betz, R. C., Blume-Peytavi, U., Callender, V., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.004 · Cited by 211
Self-citationKing, B., Guttman-Yassky, E., Peeva, E., Banerjee, A., Sinclair, R., Pavel, A. B., Zhu, L., Cox, L. A., Craiglow, B., Chen, L., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.050 · Cited by 199
Self-citationJabbari, A., Sansaricq, F., Cerise, J., Chen, J. C., Bitterman, A., Ulerio, G., Borbon, J., Clynes, R., Christiano, A. M., & Mackay-Wiggan, J. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.032 · Cited by 188
Treatment of alopecia areata: An Australian expert consensus statement
Cranwell, W. C., Lai, V. W., Photiou, L., Meah, N., Wall, D., Rathnayake, D., Joseph, S., Chitreddy, V., Gunatheesan, S., Sindhu, K., et al. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.12941 · Cited by 181
Self-citationHealth-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
Liu, L. Y., King, B. A., & Craiglow, B. G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.035 · Cited by 176
Self-citationBretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172
Wyrwich, K. W., Kitchen, H., Knight, S. L., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N. A., Ko, J., & King, B. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18883 · Cited by 134
Self-citationAldhouse, N. V. J., Kitchen, H., Knight, S. L., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N. A., Ko, J., King, B., & Wyrwich, K. W. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00240-7 · Cited by 129
Self-citationKing, B., Ko, J., Forman, S. B., Ohyama, M., Mesinkovska, N. A., Yu, G., McCollam, J. S., Gamalo, M., Janes, J., Edson‐Heredia, E., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.05.050 · Cited by 119
Self-citationLiu, L., King, B., & Craiglow, B. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.048 · Cited by 117
Self-citationJAK Inhibitors for Treatment of Alopecia Areata
Wang, E. H. C., Sallee, B. N., Tejeda, C. I., & Christiano, A. M. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.05.027 · Cited by 86
Wyrwich, K. W., Kitchen, H., Knight, S. L., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N. A., Ko, J., & King, B. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00545-9 · Cited by 80
Self-citationDevelopment of the Scalp Hair Assessment PRO™ measure for alopecia areata
Wyrwich, K. W., Kitchen, H., Knight, S. L., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N. A., Ko, J., & King, B. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19024 · Cited by 48
Self-citation
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00222-2 · Cited by 298
Self-citationBaricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Hu, B. D., He, H., Bose, S., Gour, D., Nandymazumdar, M., Zhou, J., Golla, A., del Duca, E., Beaziz, J., Avallone, G., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.02.014 · Cited by 5
Metadata
- Authors
- King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., Chiasserini, C., Yu, G., Stanley, S., Holzwarth, K., DeLozier, A. M., & Sinclair, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-05-05
- Volume
- 386
- Issue
- 18
- Pages
- 1687-1699
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4220917957
- Cited by
- 506
- References
- 26
- FWCI
- 98.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.